Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

Bausch & Lomb is one of the largest vision care ... so contact lens wearers will usually purchase a new solution every three months. Biotrue is also a more expensive solution compared with generic ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Shares of contact lens supplier Bausch + Lomb (BLCO) are surging in today ... a company specializing in surgical eye care ...

including Biotrue and SofLens. We are still impressed at the overall performance and believe the firm's share in the contact lens market slightly increased. Miebo and Xiidra, Bausch & Lomb's dry ...

It isn't known whether Bausch + Lomb and/or Goldman is in contact with either Blackstone or TPG. According to the FT, several private equity funds mulling offers have dropped out of the race.

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target of $23.00. Yi Chen has given his Buy rating due to a ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Private equity groups TPG and Blackstone have teamed up to work on a joint bid for eyecare company Bausch ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.